337.61

1.90% 6.29

After Hours: 337.61

Madrigal Pharmaceuticals Inc (MDGL)

Overview News Price History Option Chain Financials Why MDGL Down? Discussions Forecast Stock Split

Madrigal Pharmaceuticals Inc stock is traded at $337.61, with a volume of 769.60K. It is up +1.90% in the last 24 hours and up +61.99% over the past month. Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Previous Close:

$331.32

Open:

$331

24h Volume:

769.60K

Relative Volume:

2.19

Market Cap:

$7.25B

Revenue:

Net Income/Loss:

$-510.45M

P/E Ratio:

-17.55

EPS:

-19.24

Net Cash Flow:

$-455.82M

1W Performance:

+55.02%

1M Performance:

+61.99%

6M Performance:

+46.89%

1Y Performance:

+129.84%

1-Day Range:

$316.67

$337.63

1-Week Range:

$213.71

$337.63

52-Week Range:

$133.99

$337.63

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name

Madrigal Pharmaceuticals Inc

Sector

Healthcare (1182)

Industry

Biotechnology (671)

Phone

404-380-9263

Address

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Employee

376

Twitter

@MadrigalPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

MDGL's Discussions on Twitter

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-22	Reiterated	Oppenheimer	Outperform
Dec-19-22	Reiterated	H.C. Wainwright	Buy
Dec-19-22	Reiterated	Piper Sandler	Overweight
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy
Nov-24-20	Resumed	Evercore ISI	Outperform
Nov-06-20	Reiterated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-05-20	Initiated	BMO Capital Markets	Market Perform
May-05-20	Initiated	Chardan Capital Markets	Buy
Jan-30-20	Initiated	Canaccord Genuity	Buy
Jan-09-20	Upgrade	UBS	Neutral → Buy
Nov-07-19	Reiterated	H.C. Wainwright	Buy
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-28-19	Reiterated	H.C. Wainwright	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform
Jan-23-19	Initiated	UBS	Neutral
Dec-14-18	Initiated	Wolfe Research	Outperform
Dec-12-18	Initiated	B. Riley FBR	Neutral
Nov-19-18	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-18	Upgrade	Evercore ISI	In-line → Outperform
Sep-04-18	Initiated	Citigroup	Buy
Aug-06-18	Downgrade	Goldman	Buy → Neutral
Jun-28-18	Initiated	Raymond James	Mkt Perform

View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

11:35 AM

B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat

11:35 AM

Nov 04, 2024

Check Out What Whales Are Doing With MDGL - Benzinga

Nov 04, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst Upgrade - MarketBeat

Nov 04, 2024

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance

Nov 04, 2024

What is Leerink Partnrs' Forecast for MDGL FY2028 Earnings? - MarketBeat

Nov 04, 2024

Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Nov 04, 2024

Nov 03, 2024

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga

Nov 03, 2024

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha

Nov 03, 2024

Nov 02, 2024

(MDGL) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance

Nov 02, 2024

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St

Nov 02, 2024

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance

Nov 02, 2024

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN

Nov 02, 2024

Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN

Nov 02, 2024

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa

Nov 01, 2024

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN

Nov 01, 2024

Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily

Nov 01, 2024

Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 at UBS Group - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Beats Estimates By $2.02 EPS - MarketBeat

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 - Investing.com

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume After Strong Earnings - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance

Nov 01, 2024